Showing results (1-10 of 82) with videos related to
Sort By:
Pageof 9
Respiratory Medicine and Research|June 12, 2023
Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapyClarisse Audigier Valette, Thomas Filleron, Didier Debieuvre, et al.European Journal of Cancer (Oxford, England : 1990)|January 11, 2022
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position articleJérôme Barrière, Michel Carles, Clarisse Audigier-Valette, et al.Expert Review of Anticancer Therapy|October 27, 2017
The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastasesLinda Bouhlel, Véronique Hofman, Célia Maschi, et al.Cancer Medicine|June 7, 2026
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in FranceDidier Debieuvre, Pauline Macouillard, Xavier Quantin, et al.Bulletin Du Cancer|October 10, 2014
[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?]Clarisse Audigier-Valette, Nicolas Girard, Alexis B Cortot, et al.Expert Review of Anticancer Therapy|November 22, 2014
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?Nicolas Girard, Clarisse Audigier-Valette, Alexis B Cortot, et al.Targeted Oncology|August 15, 2014
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLCCecile Bosc, Gilbert R Ferretti, Jacques Cadranel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2011
Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)Chantal Decroisette, Isabelle Monnet, Henri Berard, et al.Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational studyIsabelle Monnet, Clarisse Audigier-Valette, Nicolas Girard, et al.Lung Cancer (Amsterdam, Netherlands)|January 2, 2014
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomasLénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro-Sibilot, et al.Pageof 9